Erste Asset Management GmbH Has $39.46 Million Position in Merck & Co., Inc. $MRK

Erste Asset Management GmbH raised its holdings in Merck & Co., Inc. (NYSE:MRK) by 50.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 370,971 shares of the company’s stock after buying an additional 124,202 shares during the period. Erste Asset Management GmbH’s holdings in Merck & Co., Inc. were worth $39,455,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after purchasing an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC increased its stake in shares of Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC increased its stake in shares of Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after purchasing an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Merck & Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after purchasing an additional 359,356 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reached a settlement of more than $50 million to resolve over 200 Gardasil-related lawsuits, removing a significant legal overhang and helping investors refocus on the company’s core business and pipeline. Merck Gardasil Settlement Eases Legal Overhang And Refocuses Investor Attention
• Positive Sentiment: Merck recently broke above both its 20-day and 50-day moving averages, a technical signal that traders often view as a sign of improving short-term momentum. Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
• Positive Sentiment: Merck’s oncology franchise continues to draw attention after ASCO 2026 updates highlighted Keytruda’s strength in solid tumors and other pipeline assets aimed at offsetting future exclusivity pressure. ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
• Positive Sentiment: Merck’s collaboration with Moderna on a personalized mRNA cancer vaccine also got a boost from positive long-term data disclosed by Moderna, reinforcing investor interest in the partnership. Why Is Moderna (MRNA) Stock Rocketing Higher Today
• Neutral Sentiment: Merck’s conference appearance and oncology strategy update likely kept investor focus on the pipeline, but the items available do not indicate a major new catalyst beyond ongoing progress. Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification – Slideshow

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $121.05 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $298.96 billion, a P/E ratio of 34.10, a P/E/G ratio of 2.72 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14. The firm has a 50-day moving average price of $116.55 and a two-hundred day moving average price of $112.52.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the previous year, the firm posted $2.22 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Wall Street Analyst Weigh In

MRK has been the subject of several research analyst reports. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. Wells Fargo & Company reduced their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Barclays initiated coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 target price for the company. JPMorgan Chase & Co. lifted their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a report on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.